AI Terminal
Xbrane Biopharma
Declaration of Voting Results & Voting Rights Announcements • Jun 30, 2021
3128_rns_2021-06-30_bdb370ad-a79d-4c91-8cc9-497475bfd251.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company. The number of shares and votes in Xbrane have changed following the issue of 21,791 shares during June through exercise of warrants under Warrants series II 2018/2021, adopted at the extra general meeting 2018 and under LTIP 2018, adopted at the annual general meeting 2018.
As of June 30, 2021, the total number of shares and votes in the Company amounts to 22,222,206. The Company's registered share capital amounts to SEK 4,981,908.832925.
Contacts
Martin Åmark, CEO M: +46 76 309 37 77 E: [email protected]
Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: [email protected]
About Us
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilars in its pipeline targeting € 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-06-30 12:00 CEST.